Investigator Studies Program (MISP): Clostridium difficile
Effective January 2022, the Clostridium difficile Infections (CDI) Investigator Studies Program (MISP) Committee will accept PROTOCOL
submissions within our current areas of interest (AOI) up to June 11, 2022. This is a competitive process that will be conducted by the CDI MISP in 2022. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.
The following areas are of interest to Investigator Studies Program Committee:
- Studies that are chart based which describe the use and outcomes of fidaxomicin oral suspension in adult populations
For clinical, interventional studies, please complete and submit the PROTOCOL
template and GLOBAL CLINICAL FMV BUDGET
, the Company's on-line study management system (in US) or your MSD country representative (outside US). The proposals will be collectively reviewed and selected by the CDI MISP Committee.
Critical Activities and Timelines:
|Proposal Submission & Detailed Budget
||June 11, 2022
|MISP-RC Review and selection of proposals
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator
Studies Program should contact their local MSD office